Hepatit B'den D'ye Hep Güncel - page 312

300
Kronik HDV
of chronic hepatitis D: regression of advanced hepatic fi brosis. Gastroenterology
2004; 126: 1740–49.
3. Lau DT, Kleiner DE, Park Y, Di Bisceglie AM, Hoofnagle JH. Resolution of chronic
delta hepatitis after 12 years of interferon alpha therapy. Gastroenterology 1999;
117: 1229–33.
4. Farci P. Delta hepatitis: an update. J Hepatol 2003; 39 (suppl 1): S212–19.
5. Manesis EK, Schina M, Le Gal F, et al. Quantitative analysis of hepatitis D virus RNA
and hepatitis B surface antigen serum levels in chronic delta hepatitis improves
treatment monitoring. Antivir Ther 2007; 12: 381–88.
6. Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy
or in combination with ribavirin in chronic hepatitis delta. Hepatology 2006; 44:
713–20.
7. Castelnau C, Le Gal F, Ripault MP, et al. Effi cacy of peginterferon alpha-2b in
chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology
2006; 44: 728–35.
8. Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis delta with
pegylated interferon-alpha2b. Liver Int 2006; 26: 805–10.
9. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus
either drug alone for hepatitus delta. N Engl J Med 2011; 364: 322–31.
10. Yurdaydin C, Bozkaya H, Onder FO, et al. Treatment of chronic delta hepatitis with
lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat 2008; 15: 314–21.
11. Yurdaydin C, Bozkaya H, Gurel S, et al. Famciclovir treatment of chronic delta
hepatitis. J Hepatol 2002; 37: 266–71.
12. Garripoli A, Di Marco V, Cozzolongo R, et al. Ribavirin treatment for chronic
hepatitis D: a pilot study. Liver 1994; 14: 154–57.
13. Gunsar F, Akarca US, Ersoz G, et al. Two-year interferon therapy with or without
ribavirin in chronic delta hepatitis. Antivir Ther 2005; 10: 721–26.
14. Onder F, Yakut M, Idilman R, et al. Entecavir may be benefi cial in a subset of
patients with chronic delta hepatitis. Hepatology 2009; 50 (suppl 4): 735A (abstr).
15. Mansour W, Ducancelle A, Le Gal F, et al. Resolution of chronic hepatitis Delta
after 1 year of combined therapy with pegylated interferon, tenofovir and
emtricitabine. J Clin Virol 2010; 47: 97–99.
16. Sheldon J, Ramos B, Toro C, et al. Does treatment of hepatitis B virus (HBV)
infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected
patients? Antivir Ther 2008;13: 97–102.
17. Zachou K, Yurdaydin C, Drebber U, et al, for the HIDT-1 Study Group. Quantitative
HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010; 30: 430–37.
18. Le Gal F, Gordien E, Aff olabi D, et al. Quantifi cation of hepatitis delta virus RNA
in serum by consensus real-time PCR indicates diff erent patterns of virological
response to interferon therapy in chronically infected patients. J Clin Microbiol
2005; 43: 2363–69.
19. O’Grady JG, Alexander GJ, Hayllar KM, Williams R. Early indicators of prognosis in
fulminant hepatic failure. Gastroenterology 1989; 97: 439–45.
20. Samuel D, Zignego AL, Reynes M, et al. Long-term clinical and virological
outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.
Hepatology 1995; 21: 333–39.
21. Rosenau J, Kreutz T, Kujawa M, et al. HBsAg level at time of liver transplantation
determines HBsAg decrease and anti-HBs increase and aff ects HBV DNA
decrease during early immunoglobulin administration. J Hepatol 2007; 46: 635–